卒中遗传学对临床实践的影响:现状与未来
该综述梳理卒中遗传学主要进展并回答临床医生关注的四个问题:卒中遗传架构的已知信息、单基因卒中的基因检测时机与方法、遗传信息在风险分层与预防中的应用、以及遗传发现带来的治疗启示。文章强调全基因组关联研究的成功、日益增多的单基因脑小血管病、多基因风险评分的应用与挑战,以及基因组学对卒中治疗的影响。
要点
- 全基因组关联研究已改变对卒中遗传架构的理解。
- 单基因脑小血管病种类增多,需明确基因检测时机与方法。
- 多基因风险评分受关注,但临床应用仍面临挑战。
核心结论
- 卒中遗传学进展正在影响当前临床实践并塑造未来诊疗方向。
研究设计与样本
- 综述,围绕卒中遗传学进展及对临床医生的四个相关问题进行论述。
主要发现
- 全基因组关联研究在卒中领域取得成功并改变了对卒中遗传架构的理解。
- 越来越多的单基因脑小血管病形式被识别。
- 多基因风险评分受到越来越多关注,但其应用存在挑战。
- 基因组学通过识别新靶点、孟德尔随机化评估因果及药物基因组学影响卒中治疗。
临床怎么用
- 临床医生需了解单基因卒中的基因检测时机与方法。
- 遗传信息可用于风险分层与预防。
- 关注多基因风险评分的应用及其挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Stroke, Ahead of Print. The past decade has seen a transformation in our understanding of the genetics of stroke. However, a commonly asked question is how do these advances impact the practicing clinician now, and what are their implications for clinical care in the future? This review outlines the major recent advances in stroke genetics and addresses 4 questions most relevant to the clinician: What do we now know about the genetic architecture of stroke? When and how should genetic testing be used to identify monogenic stroke? How can genetic information be applied to risk stratification and prevention? And what therapeutic implications are emerging from genetic discoveries? It highlights the success of genome-wide association studies in stroke and how these have transformed how we understand the genetic architecture of stroke. An increasing number of monogenic forms of cerebral small vessel disease are being identified, and guidance on when and how to test for them is covered. Polygenic risk scores are gaining increasing attention. How these can be applied, and the challenges in their use are discussed. Lastly, the impact of genomics on stroke therapeutics, whether by identifying new targets, assessing causality using techniques such as Mendelian randomization, or pharmacogenomics, is discussed.
引用
- Stroke:How Stroke Genetics Is Impacting Clinical Care: Now and the Future
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。